United Therapeutics Corporation (FRA:UTH)

Market Cap	17.89B
Revenue (ttm)	2.67B
Net Income (ttm)	1.08B
Shares Out	n/a
EPS (ttm)	22.48
PE Ratio	16.50
Forward PE	14.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	14
Open	421.10
Previous Close	421.00
Day's Range	421.10 - 421.10
52-Week Range	237.40 - 440.80
Beta	n/a
RSI	50.77
Earnings Date	Feb 26, 2026

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,305
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UTH

Financial Performance

In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.

Financial numbers in USD